Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01850459 · ClinicalTrials.gov registry record
Extracellular Signal-Related Kinase Biomarker Development in Autism
A clinical trial, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- 213
- Enrollment target
NCT01850459: Completed study, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT01850459 is a clinical trial that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 213 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01850459 has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- 213 participants
- Enrollment target
Study Summary
The purpose of this research study is to establish a way to help the development of targeted treatments in autism spectrum disorders. This may also help in early diagnosis of autism and may possibly predict severity. The study will compare subject's ERK (extracellular signal-related kinase) signaling to age- and gender-matched neurotypical controls and Intelligence quotient (IQ)-matched developmental disabilities.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 213 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-08 |
What the finished NCT01850459 record still lists
NCT01850459 is an observational study that tracks outcomes without assigning an intervention. The registered 213 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01850459 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01850459 about?
NCT01850459 is a clinical study titled "Extracellular Signal-Related Kinase Biomarker Development in Autism". The purpose of this research study is to establish a way to help the development of targeted treatments in autism spectrum disorders. This may also help in early diagnosis of autism and may possibly predict severity. The study will compare subject's ERK (extracellular signal-related kinase) signalin...
What is the current status of trial NCT01850459?
This trial is currently completed. The enrollment target is 213 participants. The study started on 2013-01. Estimated completion is 2015-08.
Who is sponsoring clinical trial NCT01850459?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06476886 · 213 participants · NA
Intensive Crisis Intervention
- NCT06544655 · 213 participants · Phase 1
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
- NCT07186816 · 213 participants · NA
SUpport From PEeRs to Expand Access Study - Community
- NCT04030507 · 214 participants · NA
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia